Collectively, our results identify a novel, ETV1‐dependent, oncogenic pathway in prostate cells and highlight the potential therapeutic outcome of coinhibition of EGFR and STAT3 in prostate carcinomas with ETV1 overexpression. This evidence concerns the gene ETV1 and prostate carcinoma.